Potentiation of Natriuretic Peptide Action by the β -Adrenergic Blocker Carvedilol in Hypertensive Rats: A New Antihypertensive Mechanism.

T. Yoshimoto,M. Naruse,A. Tanabe,K. Naruse,T. Seki,T. Imaki,T. Muraki,Y. Matsuda,H. Demura
DOI: https://doi.org/10.1210/endo.139.1.5644
IF: 5.051
Endocrinology
Abstract:Treatment with a β-adrenergic blocker (β-blocker) in hypertension is associated with increased plasma atrial natriuretic peptide (ANP) levels despite a decrease in cardiac overload. The mechanism and pathophysiological significance of the phenomenon remain unclear. To clarify the role of the ANP system in the antihypertensive effects of the β-blocker, we investigated the effects of carvedilol (30 mg/kg·day, orally, for 4 weeks) on the ANP system in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm). Plasma ANP levels showed a significant increase despite a significant decrease in blood pressure and heart rate in the carvedilol group. Although ANP messenger RNA levels in the heart did not change, messenger RNA levels of the natriuretic peptide-C (NP-C) receptor as a clearance receptor showed a significant decrease in both the aorta and lung in the carvedilol group. NP-C receptor densities were also significantly decreased in the lung in this group. The biological half-life of exogenous ANP in circul...
What problem does this paper attempt to address?